

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/538,291	06/10/2005		Kazufumi Yazaki	Q88235	9414	
23373	7590	09/22/2006		EXAMINER		
SUGHRUE	-		MEAH, MOHAMMAD Y			
2100 PENNSYLVANIA AVENUE, N.W. SUITE 800 WASHINGTON, DC 20037				ART UNIT	PAPER NUMBER	
				1652		
				DATE MAILED: 09/22/2006	DATE MAILED: 09/22/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)				
	10/538,291	YAZAKI ET AL.				
Office Action Summary	Examiner	Art Unit				
	Mohammad Meah	1652				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	l. ely filed the mailing date of this communication. 0 (35 U.S.C. § 133).				
Status						
Responsive to communication(s) filed on This action is FINAL.	action is non-final. ace except for formal matters, pro					
Disposition of Claims						
4) Claim(s) 1-19 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-19 are subject to restriction and/or expectation Papers 9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access	election requirement. r. epted or b) objected to by the B					
Applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Ex	on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite				

DETAILED ACTION

1. The claims 1-19 are pending in the instant office action.

Restriction

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-3, drawn to method of selection of E. coli strain.

Group II, claims 4-16, drawn to E. coli strain.

Group III, claim 17, drawn to process for the preparation of enzyme using the E. colistrain of group II.

Group IV, claim 18, drawn to process for the preparation of chemical compound using the E. coli strain of group II.

Group V, claims 18-19, drawn to process for the preparation of chemical compound using ammonia lyase.

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Technical feature of Group I, III, IV and V are method steps. Groups I, III, IV and V do not share same technical feature because method steps in these groups use different products and results different outcomes.

Though group IV uses the product of group II they do not share same technical feature because group II product can be used in other process having different technical feature such as to produce enzymes in group III.

Furthermore, the technical feature linking groups I-V appears to be that they all relate to the stress resistance E. coli strain of group II which does not constitute a "special technical feature" as defined by PCT Rule 13.2, because it does not claim a feature, which defines a contribution over the prior art as this type of E. coli strain is taught by Kenkyusho et al. (JP pat 8-140671, Abstract)

- 4. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.
- Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1652

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mohammad Younus Meah, PhD Examiner, Art Unit 1652 Recombinant Enzymes, 3C31 Remsen Bld 400 Dulany Street, Alexandria, VA 22314

Telephone: 517-272-1261

REBECCA E. PACUTY '
PRIMARY EXAMINER
GROUP-1800